LB Pharmaceuticals Inc Common Stock (LBRX)
US — Healthcare Sector
Automate Your Wheel Strategy on LBRX
With Tiblio's Option Bot, you can configure your own wheel strategy including LBRX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- Rating
- Score
- Recommendation
- P/E Score
- DCF Score
- P/B Score
- D/E Score
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | LBRX | Leerink Partners | -- | Outperform | -- | $34 | Oct. 6, 2025 |
| Initiation | LBRX | Piper Sandler | -- | Overweight | -- | $78 | Oct. 6, 2025 |
| Initiation | LBRX | Stifel | -- | Buy | -- | $27 | Oct. 6, 2025 |
News
About LB Pharmaceuticals Inc Common Stock (LBRX)
- IPO Date 2025-09-11
- Website https://lbpharma.us
- Industry Biotechnology
- CEO Heather D. Turner
- Employees 16
Clinical‑stage biopharmaceutical company developing novel therapies for neuropsychiatric diseases (e.g. schizophrenia, bipolar depression). Lead candidate is LB‑102, a methylated derivative of amisulpride.